Accuray (ARAY) said Monday that it received approval from the Chinese National Medical Products Administration for its Radixact SynC and CyberKnife S7 System.
Radixact SynC is a radiation therapy system designed to deliver precise and personalized treatment to patients with cancer and CyberKnife S7 is a robotic radiosurgery device for treating cancerous and benign tumors, the company said.
Shares of the company were up 2.1% in recent trading.
Price: 2.19, Change: +0.04, Percent Change: +2.10
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。